EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Protective Human Papillomavirus Type 16/18 Vaccine–Induced Neutralizing Antibody Levels Remain Elusive

Matti Lehtinen iD, Tiina Eriksson, Tiina Petäjä, Katja Harjula, Kaisa Heikkilä, Mari Hokkanen, Julia Butt iD, Birgitta Michels, Peter Sehr, Martin Müller, Ville Pimenoff, Tim Waterboer iD

Open Forum Infectious Diseases · 30.03.2026 · 13 (4)

DOI: 10.1093/ofid/ofag174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 01.04.2026. Verfasst von Matti Lehtinen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infections and Cancer Epidemiology, Deutsches Krebforschungzentrum, Heidelberg, Germany. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We studied human papillomavirus antibodies in a subset of a cohort comprising 16 988 women who received human papillomavirus (HPV) 16/18 vaccination as adolescents, among whom 50 cervical high-grade squamous cell intraepithelial lesions (HSILs) were diagnosed by 28 years of age. No differences in neutralizing HPV16/18 antibody levels between the HSIL cases and 1:2 matched vaccinated controls with or without persistent cervical HPV infection were observed. As compared with the HPV16/18, cross-neutralizing HPV33 antibody levels were significantly increased in the HSIL cases with concomitant cervical and serum sampling. However, during 16 years of follow-up, protective vaccine–induced, HPV16/18 cross-neutralizing (clade A9/A7 specific) antibody levels remained elusive.

Schlagwörter

Stichwörter der Autor:innen

antibodycervical neoplasiahuman papillomavirusneutralizationvaccination

Autor:innen und Institutionen

  • Infections and Cancer Epidemiology, Deutsches Krebforschungzentrum, Heidelberg, Germany.
  • Department of Clintec, Karolinska Institute, Stockholm, Sweden.
  • FICAN-Mid, Tampere, Finland.
  • Unit of Population Health, University of Oulu, Oulu, Finland.
  • EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Tumorvirus-Specific Vaccination Strategies, Deutsches Krebforschungzentrum, Heidelberg, Germany.

ORCID-Profile: Matti Lehtinen, Julia Butt, Tim Waterboer

Förderung

  • Swedish Cancerfonden

Zitieren

APA

Lehtinen, M., Eriksson, T., Petäjä, T., Harjula, K., Heikkilä, K., Hokkanen, M., Butt, J., Michels, B., Sehr, P., Müller, M., Pimenoff, V., & Waterboer, T. (2026). Protective Human Papillomavirus Type 16/18 Vaccine–Induced Neutralizing Antibody Levels Remain Elusive. Open Forum Infectious Diseases, 13(4). https://doi.org/10.1093/ofid/ofag174

Vancouver

Lehtinen M, Eriksson T, Petäjä T, Harjula K, Heikkilä K, Hokkanen M, et al. Protective Human Papillomavirus Type 16/18 Vaccine–Induced Neutralizing Antibody Levels Remain Elusive. Open Forum Infectious Diseases. 2026;13(4). doi:10.1093/ofid/ofag174

BibTeX
@article{Lehtinen2026,
  author = {Lehtinen, Matti and Eriksson, Tiina and Petäjä, Tiina and Harjula, Katja and Heikkilä, Kaisa and Hokkanen, Mari and Butt, Julia and Michels, Birgitta and Sehr, Peter and Müller, Martin and Pimenoff, Ville and Waterboer, Tim},
  title = {Protective Human Papillomavirus Type 16/18 Vaccine–Induced Neutralizing Antibody Levels Remain Elusive},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {4},
  doi = {10.1093/ofid/ofag174}
}
Kostenlos starten →